AU2009336141A1 - Combination therapies for neoplastic disorders - Google Patents

Combination therapies for neoplastic disorders Download PDF

Info

Publication number
AU2009336141A1
AU2009336141A1 AU2009336141A AU2009336141A AU2009336141A1 AU 2009336141 A1 AU2009336141 A1 AU 2009336141A1 AU 2009336141 A AU2009336141 A AU 2009336141A AU 2009336141 A AU2009336141 A AU 2009336141A AU 2009336141 A1 AU2009336141 A1 AU 2009336141A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
independently
heteroalkyl
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009336141A
Other languages
English (en)
Inventor
Kenna Anderes
Joshua R. Bliesath
Denis Drygin
Caroline B. Ho
Sean O'brien
Christopher B. Proffitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cylene Pharmaceuticals Inc
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of AU2009336141A1 publication Critical patent/AU2009336141A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2009336141A 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders Abandoned AU2009336141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14328209P 2009-01-08 2009-01-08
US61/143,282 2009-01-08
PCT/US2009/046948 WO2010080170A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Publications (1)

Publication Number Publication Date
AU2009336141A1 true AU2009336141A1 (en) 2011-08-11

Family

ID=40973134

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009336141A Abandoned AU2009336141A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Country Status (13)

Country Link
EP (1) EP2381942A1 (ko)
JP (1) JP2012514638A (ko)
KR (1) KR20110116153A (ko)
CN (1) CN102341107A (ko)
AU (1) AU2009336141A1 (ko)
BR (1) BRPI0924041A2 (ko)
CA (1) CA2749261A1 (ko)
IL (1) IL213969A0 (ko)
MX (1) MX2011007384A (ko)
RU (1) RU2011133093A (ko)
SG (1) SG172922A1 (ko)
WO (1) WO2010080170A1 (ko)
ZA (1) ZA201105755B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CN114869903A (zh) * 2022-06-14 2022-08-09 苏天生命科技(苏州)有限公司 巴弗洛霉素a1在优化急性淋系白血病化疗组合药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002298A (es) * 2006-09-01 2009-06-04 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteina quinasa y de parp.
US20100255004A1 (en) * 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
ZA201105755B (en) 2012-04-25
KR20110116153A (ko) 2011-10-25
EP2381942A1 (en) 2011-11-02
WO2010080170A1 (en) 2010-07-15
RU2011133093A (ru) 2013-02-20
SG172922A1 (en) 2011-08-29
BRPI0924041A2 (pt) 2016-01-26
IL213969A0 (en) 2011-08-31
CN102341107A (zh) 2012-02-01
CA2749261A1 (en) 2010-07-15
JP2012514638A (ja) 2012-06-28
MX2011007384A (es) 2011-12-14

Similar Documents

Publication Publication Date Title
US20100173013A1 (en) Treatment of neoplastic disorders using combination therapies
JP7206314B2 (ja) Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置
JP6736559B2 (ja) トリアゾロピリミジン化合物およびその使用
AU2017254687A1 (en) Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
US20140357636A1 (en) Treatment of Skeletal-Related Disorders
WO2015011084A1 (de) Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen
ZA200402812B (en) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine A2a receptor antagonists.
CA3172088A1 (en) Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
KR20120044281A (ko) 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
CN107667092A (zh) 作为fgfr4抑制剂的甲酰化n‑杂环衍生物
AU2017205389B2 (en) Benzothiazole amphiphiles
EP3860575A1 (en) Method for preparing and delivering bisantrene formulations
KR20160005356A (ko) 방사선완화 약제학적 제형
AU2009336141A1 (en) Combination therapies for neoplastic disorders
IL263080A (en) Treatment of neurological disorders
JP7329509B2 (ja) 中枢および末梢神経系障害の治療のためのキナーゼ阻害剤
US20210299111A1 (en) Eif4a inhibitor combinations
WO2008157365A2 (en) Vinylazacycloalkanes for treating neuropathic pain
US20230064189A1 (en) 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer
CA3138419A1 (en) Heterocyclic derivatives and use thereof
WO2020063860A1 (en) Naphthyridinone and pyridopyrimidinone compounds useful as kinases inhibitors
DE112013007543T5 (de) Neu substituierte 2-Aminoquinazolin-4(3H)-one Derivate als Malaria Aspartat protease Inhibitoren

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application